High Evidence (L1-L2)
Candidates that may be prioritised for clinical evaluation
Which of these drugs have trial evidence for their predicted new indication, and how many registered trials are cited? See Canadian medicines with clinical-trial evidence for a new indication.
Criteria
| Level | Definition | Clinical meaning |
|---|---|---|
| L1 | Multiple Phase 3 RCTs / systematic reviews | Strong support; clinical use may be considered |
| L2 | Single RCT or multiple Phase 2 trials | Moderate support; validation trials can be designed |
L1 (12 drugs)
| Drug | Indications | Link |
|---|---|---|
| Acetylcysteine | 10 | View report |
| Bendamustine | 10 | View report |
| Bromfenac | 10 | View report |
| Busulfan | 10 | View report |
| Clofarabine | 8 | View report |
| Clomipramine | 8 | View report |
| Dapsone | 1 | View report |
| Doxorubicin | 8 | View report |
| Ketamine | 1 | View report |
| Ketorolac | 3 | View report |
| Peginterferon Alfa-2A | 9 | View report |
| Ribavirin | 9 | View report |
L2 (41 drugs)
| Drug | Indications | Link |
|---|---|---|
| Atorvastatin | 4 | View report |
| Brentuximab Vedotin | 10 | View report |
| Bupropion | 10 | View report |
| Cefprozil | 10 | View report |
| Citalopram | 5 | View report |
| Clozapine | 9 | View report |
| Dasatinib | 9 | View report |
| Desoximetasone | 10 | View report |
| Diazepam | 10 | View report |
| Docetaxel | 7 | View report |
| Fludarabine | 10 | View report |
| Goserelin | 3 | View report |
| Hydrocortisone | 9 | View report |
| Hydrocortisone Acetate | 9 | View report |
| Ledipasvir | 10 | View report |
| Lenalidomide | 4 | View report |
| Levonorgestrel | 5 | View report |
| Mefenamic Acid | 6 | View report |
| Midazolam | 1 | View report |
| Moclobemide | 2 | View report |
| Montelukast | 2 | View report |
| Mycophenolate Mofetil | 10 | View report |
| Nepafenac | 10 | View report |
| Nortriptyline | 2 | View report |
| Ofatumumab | 4 | View report |
| Oxaliplatin | 4 | View report |
| Pimecrolimus | 3 | View report |
| Prednisolone | 9 | View report |
| Prednisone | 9 | View report |
| Propofol | 5 | View report |
| Regorafenib | 8 | View report |
| Risankizumab | 10 | View report |
| Sodium Oxybate | 6 | View report |
| Sodium Tetradecyl Sulfate | 10 | View report |
| Solriamfetol | 10 | View report |
| Sucralfate | 2 | View report |
| Sunitinib | 5 | View report |
| Tacrolimus | 2 | View report |
| Tizanidine | 5 | View report |
| Ustekinumab | 10 | View report |
| Vinorelbine | 8 | View report |
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)